6 research outputs found
Composition comprisin Creb3L1/CrebA protein or polynucleotide encoding the CrebA/CREB3L1 for the prevention or treatment of neurodegenerative disease
๋ณธ ๋ฐ๋ช
์ CrebA/CREB3L1 ๋จ๋ฐฑ์ง ๋๋ ์ด๋ฅผ ์ํธํํ๋ ํด๋ฆฌ๋ดํด๋ ์คํฐ๋๋ฅผ ์ ํจ์ฑ๋ถ์ผ๋ก ํจ์ ํ๋ ํดํ์ฑ๋์งํ์ ์๋ฐฉ ๋๋ ์น๋ฃ์ฉ ์ฝํ์ ์กฐ์ฑ๋ฌผ์ ๊ดํ ๊ฒ์ผ๋ก, ๊ตฌ์ฒด์ ์ผ๋ก CrebA/CREB3L1๋จ๋ฐฑ์ง์ Machado-Joseph disease์ MJDtr-78Q ๋จ๋ฐฑ์ง ๋
์ฑ์ผ๋ก ์ ๋ฐ๋ ์์๋๊ธฐ์ GOP๊ธฐ๋ฅ์ฅ์ ๋ฐ ์ํ์ง๋ง ์์ค์ ํ๋ณต์ํค๊ณ , C4da ์ ๊ฒฝ์ธํฌ ์์๋๊ธฐ์ ์์ค์ ์ต์ ํ๋ฉฐ, ์์๋๊ธฐ ๊ฐ์ง์ ํํ๋ฅผ ํ๋ณต์ํค๊ณ , polyQ ๋
์ฑ์ผ๋ก ์ ํด๋ ์ํฌ๋งค๊ฐ์์ก, ๋ง๊ตฌ์กฐํ, ์ง์งํฉ์ฑ๊ณผ CrebA์ด ๊ฐํ๊ฒ ์ฐ๊ด๋์ด ์๋ ๊ฒ์ ํ์ธํ์์ผ๋ฉฐ, ์ฌ๋์ ๋ HEK293T ์ธํฌ์ฃผ์์ CREB3L1 ๋ฐ ์ธํฌ๋ง ์์ก๊ณผ ๊ด๋ จ๋ Sec13 ๋ฐ Sec23A์ ๋ฐํ์ด polyQ๋
์ฑ์ ์ํด ๊ฐ์ํ๋ ๊ฒ์ ํ์ธํจ์ผ๋ก์จ, ๋ณธ ๋ฐ๋ช
์ CrebA/CREB3L1 ๋จ๋ฐฑ์ง ๋ฐ ์ด๋ฅผ ์ํธํํ๋ ๋ดํด๋ ์คํฐ๋๋ ํดํ์ฑ๋์งํ์ ์๋ฐฉ ๋๋ ์น๋ฃ์ฉ ์กฐ์ฑ๋ฌผ๋ก์จ ์ ์ฉํ๊ฒ ์ฌ์ฉ๋ ์ ์๋ค.CrebA/CREB3L1(cAMP-response element-binding protein/cAMP-response element-binding protein 3 like 1)๋จ๋ฐฑ์ง ๋๋ ์ด๋ฅผ ์ํธํ ํ๋ ํด๋ฆฌ๋ดํด๋ ์คํฐ๋๋ฅผ ์ ํจ์ฑ๋ถ์ผ๋ก ํจ์ ํ๋ ํดํ์ฑ๋์งํ์ ์๋ฐฉ ๋๋ ์น๋ฃ์ฉ ์ฝํ์ ์กฐ์ฑ๋ฌผ๋ก์,์๊ธฐ ํดํ์ฑ๋์งํ์ ์ฒ์์ด๋์๋์ค์ฆ 1, 2, 6, 7 ๋ฐ 17ํ(spinocerebellar ataxias(SCA) types 1, 2, 6, 7 and 17), ๋ง์ฐจ๋-์กฐ์
์งํ(Machado-Joseph disease, MJD/SCA3), ํํ
ํด๋ณ(Huntington's disease), ์น์ํต์ ํต๋ด์ฐฝ๊ตฌ ์์ํํต ์์ถ์ฆ(dentatorubral pallidoluysian atrophy, DRPLA), X-์ฐ๊ด ์ฒ์์ฑ ๊ทผ์ก์์ถ์ฆ 1(spinal and bulbar muscular atrophy, X-linked 1, SMAX1/SBMA), ๋ฐ ๊ทผ์์ถ์ฑ์ธก์ญ๊ฒฝํ์ฆ(amyotrophic lateral sclerosis)์ผ๋ก ๊ตฌ์ฑ๋ ๊ตฐ์ผ๋ก๋ถํฐ ์ ํ๋ ๊ฒ์ธ ์ฝํ์ ์กฐ์ฑ๋ฌผ
Screening platform for assessing cellular and behavioral defects in Drosophila Melanogaster
For screening drugs or molecules that can modify disease pathophysiology of human disease or conduct drug screening, the use of appropriate in vivo model with low expenditure suitable for large-scale screening is essential. Drosophila Melanogaster, whose genome contain orthologs for 75% of human disease-related genes, offers a quantitative screening platform for assessing both cellular and behavioral defects that are thought to be representative of human diseases like Parkinsonโs
disease(PD), Huntingtonโs disease(HD) or amyotrophic lateral sclerosis(ALS). Here, we present the low cost screening analysis platform available for measuring cellular and behavioral defects in Drosophila. This platform can be adapted for the use of therapeutic target discovery process as an economic and powerful in vivo screening tool for the researchers